Such deletions include PARD6 (PAR6) in lung cancer, PARD3 (PAR3) in lung, head and neck, esophagus, prostate and bladder cancers, and DLG2 in lung and cervical cancers [140, 141]. Here, PARD3 is linked to lung carcinoma.